Format

Send to

Choose Destination
Eur J Surg Oncol. 2017 May;43(5):949-962. doi: 10.1016/j.ejso.2017.01.010. Epub 2017 Jan 29.

Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?

Author information

1
Institut Curie, PSL Research University, Department of Medical Oncology, Paris, France; Institut Curie, PSL Research University, Circulating Tumor Biomarkers Laboratory, SiRIC, Paris, France.
2
Institut Curie, PSL Research University, Circulating Tumor Biomarkers Laboratory, SiRIC, Paris, France.
3
Institut Curie, PSL Research University, Department of Surgical Oncology, Paris, France.
4
Institut Curie, PSL Research University, Department of Medical Oncology, Paris, France.
5
Institut Curie, PSL Research University, Department of Genetics, Paris, France; Université Paris Descartes, Paris, France.
6
Institut Curie, PSL Research University, Department of Medical Oncology, Paris, France; Institut Curie, PSL Research University, Circulating Tumor Biomarkers Laboratory, SiRIC, Paris, France; Université Paris Descartes, Paris, France.
7
Institut Curie, PSL Research University, Department of Medical Oncology, Paris, France; Institut Curie, PSL Research University, Circulating Tumor Biomarkers Laboratory, SiRIC, Paris, France; Université Paris-Saclay, Saint Cloud, France.

Abstract

As a result of recent progress in detection techniques, circulating tumor DNA (ctDNA) and circulating tumor cells (CTC) can now be accurately detected in the blood of most cancer patients. While these new biomarkers can provide a better understanding of key biological mechanisms underlying cancer growth and dissemination, they also open up a wide range of possible clinical applications in medical oncology, radiation oncology and surgical oncology. In this review, we summarize the results obtained with ctDNA and CTC together with their potential future clinical applications in the field of surgical oncology, with particular focus on the perioperative setting of various types of cancer. These applications include, but are not limited to, cancer screening, early diagnosis, prognostic assessment, evaluation and management of preoperative systemic or local therapies, post-surgical detection of minimal residual disease and early detection of cancer relapse.

KEYWORDS:

Circulating tumor DNA; Circulating tumor cells; Minimal residual disease; Neoadjuvant; Surgery

PMID:
28185687
DOI:
10.1016/j.ejso.2017.01.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center